EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Clinical Efficacy of Probiotics for Allergic Rhinitis: Results of an Exploratory Randomized Controlled Trial

Lisa Lungaro iD, Patrizia Malfa iD, Francesca Manza iD, Anna Costanzini iD, Guido Valentini, Diletta Francesca Squarzanti iD, Elisa Viciani iD, Alena Velichevskaya, Andrea Castagnetti iD, Marianna Barbalinardo, Denis Gentili iD, Alessio Cariani und 4 weitere

Nutrients · 30.11.2024 · 16 (23) · 4173

DOI: 10.3390/nu16234173 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 30.11.2024. Verfasst von Lisa Lungaro und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy. Hauptthemen laut MEDLINE: Probiotics, Quality of Life, Rhinitis, Allergic. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Ferrara.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allergic Rhinitis (AR) is an atopic disease affecting the upper airways of predisposed subjects exposed to aeroallergens. This study evaluates the effects of a mix of specific probiotics (L. acidophilus PBS066, L. rhamnosus LRH020, B. breve BB077, and B. longum subsp. longum BLG240) on symptoms and fecal microbiota modulation in subjects with AR.

Methods

Probiotic effects were evaluated at the beginning (T0), at four and eight weeks of treatment (T1 and T2, respectively), and after four weeks of follow-up from the end of treatment (T3) (n = 19) compared to the placebo group (n = 22). AR symptoms and quality of life were evaluated by the mini rhinitis quality of life questionnaire (MiniRQLQ) at each time point. Allergic immune response and fecal microbiota compositions were assessed at T0, T2, and T3. The study was registered on Clinical-Trial.gov (NCT05344352).

Results

The probiotic group showed significant improvement in the MiniRQLQ score at T1, T2, and T3 vs. T0 (p < 0.01, p < 0.05, p < 0.01, respectively). At T2, the probiotic group showed an increase in Dorea, which can be negatively associated with allergic diseases, and Fusicatenibacter, an intestinal bacterial genus with anti-inflammatory properties (p-value FDR-corrected = 0.0074 and 0.013, respectively). Conversely, at T3 the placebo group showed an increase in Bacteroides and Ruminococcaceae unassigned, (p-value FDR-corrected = 0.033 and 0.023, respectively) which can be associated with allergies, while the probiotic group showed a significative increase in the Prevotella/Bacteroides ratio (p-value FDR-corrected = 0.023).

Conclusions

This probiotic formulation improves symptoms and quality of life in subjects with AR, promoting a shift towards anti-inflammatory and anti-allergic bacterial species in the intestinal microbiota.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsQuality of LifeRhinitis, AllergicAdultFemaleHumansMaleMiddle AgedYoung AdultDouble-Blind MethodFecesGastrointestinal MicrobiomeLacticaseibacillus rhamnosusLactobacillus acidophilusTreatment Outcome

Stichwörter der Autor:innen

allergic rhinitisimmune systeminflammationmicrobiotaprobiotics

Autor:innen und Institutionen

  • Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
  • SynBalance Srl, 21040 Origgio, Italy.
  • Wellmicro Srl, 40138 Bologna, Italy.
  • Institute for the Study of Nanostructured Materials (CNR-ISMN), National Research Council, 40129 Bologna, Italy.
  • Analysis Laboratory, St. Anna Hospital, 44121 Ferrara, Italy.
  • Complex Operational Unit of Internal Medicine, S.S. Annunziata Hospital, Cento, 44121 Ferrara, Italy.

ORCID-Profile: Lisa Lungaro, Patrizia Malfa, Francesca Manza, Anna Costanzini, Diletta Francesca Squarzanti, Elisa Viciani, Andrea Castagnetti, Denis Gentili, Sara Ghisellini, Fabio Caputo, Roberto De Giorgio, Giacomo Caio

Förderung

  • University of Ferrara

Zitieren

APA

Lungaro, L., Malfa, P., Manza, F., Costanzini, A., Valentini, G., Squarzanti, D. F., Viciani, E., Velichevskaya, A., Castagnetti, A., Barbalinardo, M., Gentili, D., Cariani, A., Ghisellini, S., Caputo, F., De Giorgio, R., & Caio, G. (2024). Clinical Efficacy of Probiotics for Allergic Rhinitis: Results of an Exploratory Randomized Controlled Trial. Nutrients, 16(23), 4173. https://doi.org/10.3390/nu16234173

Vancouver

Lungaro L, Malfa P, Manza F, Costanzini A, Valentini G, Squarzanti DF, et al. Clinical Efficacy of Probiotics for Allergic Rhinitis: Results of an Exploratory Randomized Controlled Trial. Nutrients. 2024;16(23):4173. doi:10.3390/nu16234173

BibTeX
@article{Lungaro2024,
  author = {Lungaro, Lisa and Malfa, Patrizia and Manza, Francesca and Costanzini, Anna and Valentini, Guido and Squarzanti, Diletta Francesca and Viciani, Elisa and Velichevskaya, Alena and Castagnetti, Andrea and Barbalinardo, Marianna and Gentili, Denis and Cariani, Alessio and Ghisellini, Sara and Caputo, Fabio and De Giorgio, Roberto and Caio, Giacomo},
  title = {Clinical Efficacy of Probiotics for Allergic Rhinitis: Results of an Exploratory Randomized Controlled Trial},
  journal = {Nutrients},
  year = {2024},
  volume = {16},
  number = {23},
  pages = {4173},
  doi = {10.3390/nu16234173}
}
Kostenlos starten →